Company Number: 15252960

Analysis Date: 2025-07-29 20:05 UTC

1. Credit Opinion: DECLINE. Vitalonga Pharma Ltd shows a negative net asset position (£-11,059) driven by current liabilities (£11,160) far exceeding current assets (£1). This indicates an immediate liquidity concern and inability to meet short-term obligations. The company is newly incorporated (Nov 2023) with minimal operating history and only one employee, which heightens risk. Absence of positive working capital and negative equity suggests weak financial footing and poor capacity to service debt or credit facilities at present.

2. Financial Strength: The balance sheet reveals net current liabilities of £11,159 and total net assets of negative £11,059. Called up share capital is only £100, indicating minimal equity buffer. No fixed assets are reported. The company’s micro-entity classification and very limited financial data restrict detailed analysis, but the negative net asset position signals insolvency from an accounting perspective. This undermines financial strength and creditworthiness.

3. Cash Flow Assessment: Current assets are nominal (£1), implying negligible cash or receivables. Current liabilities total £11,160 due within one year, indicating a significant cash outflow requirement with no apparent liquid resources. Negative net current assets mean working capital is insufficient to fund operations or repay current debts. Cash flow is likely under severe strain, raising high risk of default on payment obligations.

4. Monitoring Points:

• Improvement in net current assets and movement to positive working capital.
• Generation of positive operating cash flow and increase in liquid assets.
• Growth in share capital or equity injections to restore balance sheet strength.
• Timely payment of trade and financial creditors to avoid defaults.
• Expansion of business activity and revenue to support financial sustainability.